Risedronate positively affects osteogenic differentiation of human mesenchymal stromal cells

Archives of Medical Research

Volumn 44, Issue 5, 2013, Pages 325-334

  Casado Díaz, Antonio ^a   Santiago Mora, Raquel ^a   Dorado, Gabriel ^b   Quesada Gómez, José Manuel ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b UNIVERSITY OF CÓRDOBA   (Spain)

Author keywords

Adipocyte differentiation; Mesenchymal stromal cell; Osteoblast differentiation; Osteoporosis; Risedronate

Indexed keywords

ALKALINE PHOSPHATASE; COLLAGEN TYPE 1; DEXAMETHASONE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LIPOPROTEIN LIPASE; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; RISEDRONIC ACID; TRANSCRIPTION FACTOR RUNX2; BONE DENSITY CONSERVATION AGENT; ETIDRONIC ACID; RUNX2 PROTEIN, HUMAN;

ADIPOCYTE; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STROMA CELL; OSTEOBLAST; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADOLESCENT; ADULT; ANALOGS AND DERIVATIVES; BONE; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; FEMALE; GENETICS; METABOLISM; OSTEOCLAST; YOUNG ADULT;

ADIPOCYTES; ADOLESCENT; ADULT; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CELL DIFFERENTIATION; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; ETIDRONIC ACID; FEMALE; GENE EXPRESSION; HUMANS; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; YOUNG ADULT;

EID: 84883361729     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.05.002     Document Type: Article

References (40)

1. Russell R.G. Bisphosphonates: the first 40 years. Bone 2011, 49:2-19.
2. Russell R.G., Watts N.B., Ebetino F.H., et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
3. Fisher J.E., Rogers M.J., Halasy J.M., et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation invitro. Proc Natl Acad Sci USA 1999, 96:133-138.
4. Fisher J.E., Rodan G.A., Reszka A.A. Invivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000, 141:4793-4796.
5. Dunford J.E., Rogers M.J., Ebetino F.H., et al. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 2006, 21:684-694.
6. Xiong Y., Yang H.J., Feng J., et al. Effects of alendronate on the proliferation and osteogenic differentiation of MG-63 cells. J Int Med Res 2009, 37:407-416.
7. Reinholz G.G., Getz B., Pederson L., et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res 2000, 60:6001-6007.
8. Wang C.Z., Chen S.M., Chen C.H., et al. The effect of the local delivery of alendronate on human adipose-derived stem cell-based bone regeneration. Biomaterials 2010, 31:8674-8683.
9. Im G.I., Qureshi S.A., Kenney J., et al. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004, 25:4105-4115.
10. Idris A.I., Rojas J., Greig I.R., et al. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation invitro. Calcif Tissue Int 2008, 82:191-201.
11. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
12. Meunier P., Aaron J., Edouard C., et al. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res 1971, 80:147-154.
13. Duque G. Bone and fat connection in aging bone. Curr Opin Rheumatol 2008, 20:429-434.
14. Muruganandan S., Roman A.A., Sinal C.J. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci 2009, 66:236-253.
15. Hodsman A.B., Bauer D.C., Dempster D.W., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005, 26:688-703.
16. Casado-Diaz A., Santiago-Mora R., Jimenez R., et al. Cryopreserved human bone marrow mononuclear cells as a source of mesenchymal stromal cells: application in osteoporosis research. Cytotherapy 2008, 10:460-468.
17. Duque Gand Rivas D. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 2007, 22:1603-1611.
18. Duque G., Li W., Adams M., et al. Effects of risedronate on bone marrow adipocytes in postmenopausal women. Osteoporos Int 2011, 22:1547-1553.
19. Bobba Rand Adachi J.D. Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. Clin Interv Aging 2007, 2:275-282.
20. Gregory C.A., Gunn W.G., Peister A., et al. An Alizarin red-based assay of mineralization by adherent cells in culture: comparison with cetylpyridinium chloride extraction. Anal Biochem 2004, 329:77-84.
21. Favus M.J. Bisphosphonates for osteoporosis. N Engl J Med 2010, 363:2027-2035.
22. Roelofs A.J., Thompson K., Ebetino F.H., et al. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 2010, 16:2950-2960.
23. Kwak H.B., Kim J.Y., Kim K.J., et al. Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss. Biol Pharm Bull 2009, 32:1193-1198.
24. Orriss I.R., Key M.L., Colston K.W., et al. Inhibition of osteoblast function invitro by aminobisphosphonates. J Cell Biochem 2009, 106:109-118.
25. Koch F.P., Merkel C., Al-Nawas B., et al. Zoledronate, ibandronate and clodronate enhance osteoblast differentiation in a dose dependent manner-a quantitative invitro gene expression analysis of Dlx5, Runx2, OCN, MSX1 and MSX2. J Craniomaxillofac Surg 2011, 39:562-569.
26. Kim H.K., Kim J.H., Abbas A.A., et al. Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study. Clin Orthop Relat Res 2009, 467:3121-3128.
27. Klein B.Y., Ben-Bassat H., Breuer E., et al. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors. J Cell Biochem 1998, 68:186-194.
28. Kang A.R., Oh Y.R., Kim H.Y., et al. Up-regulation of inhibitors of DNA binding/differentiation gene during alendronate-induced osteoblast differentiation. Arch Gynecol Obstet 2012, 285:1331-1338.
29. Mitchell D.Y., Barr W.H., Eusebio R.A., et al. Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration. Pharm Res 2001, 18:166-170.
30. Ogura Y., Gonsho A., Cyong J.C., et al. Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption. J Bone Miner Metab 2004, 22:120-126.
31. Black D.M., Greenspan S.L., Ensrud K.E., et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003, 349:1207-1215.
32. Wu X., Pang L., Lei W., et al. Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell 2010, 7:571-580.
33. Johnston S., Andrews S., Shen V., et al. The effects of combination of alendronate and human parathyroid hormone (1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice. Endocrinology 2007, 148:4466-4474.
34. Arrington S.A., Fisher E.R., Willick G.E., et al. Anabolic and antiresorptive drugs improve trabecular microarchitecture and reduce fracture risk following radiation therapy. Calcif Tissue Int 2010, 87:263-272.
35. Yao W., Su M., Zhang Q., et al. Risedronate did not block the maximal anabolic effect of PTH in aged rats. Bone 2007, 41:813-819.
36. Jin J., Wang L., Wang X.K., et al. Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation. J Surg Res 2013, 180:e21-e29.
37. Bianco P. Bone and the hematopoietic niche: a tale of two stem cells. Blood 2011, 117:5281-5288.
38. Calvi L.M., Adams G.B., Weibrecht K.W., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
39. Visnjic D., Kalajzic Z., Rowe D.W., et al. Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 2004, 103:3258-3264.
40. Soki F.N., Li X., Berry J., et al. The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches. J Cell Biochem 2013, 114:67-78.